Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma

Hansen, Aaron R., Hughes, Brett G., Paul, Sanjoy, Steadman, Peter, Sommerville, Scott, Dickinson, Ian C., Walpole, Euan T., Thomson, Damien B., Mar Fan, Helen G. and Joubert, Warren L. (2014) Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma. Asia-Pacific Journal of Clinical Oncology, 1-7. doi:10.1111/ajco.12167


Author Hansen, Aaron R.
Hughes, Brett G.
Paul, Sanjoy
Steadman, Peter
Sommerville, Scott
Dickinson, Ian C.
Walpole, Euan T.
Thomson, Damien B.
Mar Fan, Helen G.
Joubert, Warren L.
Title Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma
Journal name Asia-Pacific Journal of Clinical Oncology   Check publisher's open access policy
ISSN 1743-7555
1743-7563
Publication date 2014-02-20
Year available 2014
Sub-type Article (original research)
DOI 10.1111/ajco.12167
Open Access Status Not Open Access
Start page 1
End page 7
Total pages 7
Place of publication Chichester, West Sussex, United Kingdom
Publisher Wiley-Blackwell Publishing
Language eng
Formatted abstract
Aims: Perioperative chemotherapy has improved the prognosis for patients with operable osteosarcoma. The literature is conflicting about which regimen is optimal. The aim of this study was to evaluate the survival outcomes of two cohorts of patients with operable osteosarcoma treated with different perioperative chemotherapy regimens.

Methods: This was a retrospective review of patients diagnosed with operable osteosarcoma treated at the Princess Alexandra Hospital from 1986 to 2009. The standard perioperative chemotherapy regimen changed from the modified T10 Rosen protocol to cisplatin/doxorubicin in 1997. Using the Kaplan-Meier method, overall survival (OS) and disease-free survival (DFS) curves were generated for the cisplatin/doxorubicin and the modified T10 Rosen cohorts.

Results: Seventy-one patients were identified of whom 63 had potentially curable disease. Of these, 24 received the modified T10 Rosen regimen and 39 received cisplatin/doxorubicin. There was a non-significant trend toward better OS and DFS in the patients who received the modified T10 Rosen protocol.

Conclusion: The trend toward poorer survival in the cisplatin/doxorubicin cohort, in combination with current evidence, has prompted our institution to change its practice.
Keyword Methotrexate
Osteosarcoma
Perioperative chemotherapy
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Published online ahead of print 20 February 2014.

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2015 Collection
School of Public Health Publications
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 21 Oct 2014, 12:38:36 EST by System User on behalf of School of Public Health